Stock News

Enter Stock SymbolLeaner Pfizer Positioned to Boost R&D OutputCompany’s recent decisions will enable it to concentrate on building core business Continue reading...Wed, 11 Sep 2019 19:50:48 +0000 —Read more…Pfizer is a Top Drugmaker: Is it the Right Time to Buy It?Pfizer (PFE) sales in the second half may take a hit due to business development activity, incremental currency headwinds and potentially lower sales of key drugs Prevnar and Xeljanz.Fri, 06 Sep 2019 15:57:03 +0000 —Read more…Pfizer Stock Is A Top Pharma Company — But Should You Buy It?Pfizer stock has tumbled, below other pharmaceutical stocks. Recent news has been upbeat with a drug approval and acquisitions. But the question remains: Is Pfizer stock a buy right now?Thu, 05 Sep 2019 13:00:19 +0000 —Read more…Mapi Pharma to Present Series of Recent Advancements for Treating Multiple Sclerosis (MS) at ECTRIMS 2019Results for Glatiramer Acetate (GA) Depot 3 year analysis in RRMS, GA Depot safety results in RRMS and PPMS, and novel anti-BMP for remyelination will be presented ECTRIMS 2019.Wed, 04 Sep 2019 11:00:00 +0000 —Read more…Acorda (ACOR) Down More Than 60% in 3 Months: Here's WhyAcorda's (ACOR) lead MS drug Ampyra is hit by generic rivalry in the United States, which is hurting the company's top line. Parkinson's disease drug Inbrija can be an ideal replacement.Tue, 03 Sep 2019 15:00:03 +0000 —Read more…The 3 Worst Health Care Stocks So Far This YearIt hasn’t been the greatest eight months for the health-care sector, but for three companies it’s been particularly a particularly bad year.Tue, 03 Sep 2019 10:45:00 +0000 —Read more…3 Big Stock Charts for Friday: Mylan, Newell and Home DepotFor the first time in over a week, the market moved the same direction two days in a row. The S&P 500 made a 1.27% gain on Thursday, though that still leaves it below the key 50-day moving average line. The volume behind the advance wasn't exactly thrilling either.Source: Shutterstock Computer company Dell Technologies (NYSE:DELL) took the lead, gaining more than 3% during the regular-hours session in front of earnings, and then jumping more than 9% in after-hours action after reporting an earnings beat after the closing bell rang.Holding the market back more than any other name was Fastly (NYSE:FSLY). Although it rallied more than 2% after the closing bell rang, that move didn't even come close to offsetting the stock's 12.5% setback during the normal session … a move mostly prompted by profit-taking after an incredible runup since mid-August.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks to Buy for September As for names worth a look as trading prospects headed into the long weekend though, take a look at the stock charts of Mylan (NASDAQ:MYL), Home Depot (NYSE:HD) and Newell (NASDAQ:NWL). Here's what's most noteworthy, and how that may point to what lies ahead. Newell (NWL)Newell shares have been fighting a losing battle since the middle of 2017. And, technically speaking, it's still within the confines of a well-established downtrend.On the other hand, thanks to a slow turnaround effort that started to take shape just a few weeks ago, NWL stock is close to snapping its way out of the slump. Just know that Newell has been in this condition before, only to be up-ended before it took off. But, this time it is shaping up a little bit differently. * Click to EnlargeThe upper edge of the bearish trend is the convergence of the white 200-day moving average line, and the dashed blue line that connects all the key highs going back to the beginning of last year. * Underscoring the budding bullish effort thus far is the fact that the Chaikin line is now back above zero, suggesting there's a healthy amount of volume behind the current advance. * If the prospective breakout ends up taking shape, the most plausible upside target is the 38.2% Fibonacci retracement level of $28.85. A move to that mark still wouldn't be in a straight line though. Home Depot (HD)The past couple of weeks have been good ones for Home Depot, and things were particularly hot yesterday. Thursday's 2% pop carried shares above a near-term ceiling, to bring the two-week advance to 13%. The move, however, also stopped right at another, more established technical ceiling.That momentum is compelling to be sure, particularly given how it first took shape. But, the odds of there being any more upside left to dish out are pretty slim, given everything else evident on the chart. * 7 Mega-Cap Tech Stocks on a Rebound Now * Click to EnlargeThe rally appears to have been capped at the resistance level that aligns Thursday's high with the peaks made in September and January of last year. It's the upper of the two blue lines that frame the rising trading range marked on the weekly chart. * HD stock has also now punched through the upper boundary of a shorter-term trading range, marked by red dashed lines on both stock charts. This hints at a breakout, but the sheer scope of the advance thus far is unusually big. * Underscoring the above-average odds of a pullback from here is the fact that the weekly chart's RSI indicator is very near its overbought level. Mylan (MYL)Finally, Mylan has been routed since the beginning of 2018. In fact, it looked downright unsalvageable in May thanks to a hard-hitting selloff.In some ways though, that drubbing may have ultimately been the best thing for it. Although Mylan shares have yet to work their way back into a bullish mode -- and are still far from it -- the recent action suggests May's meltdown may have served as a capitulation. Better still, the proverbial lines in the sand are pretty clear. * Click to EnlargeThe pinnacle line in the sand is the falling resistance line that connects all the peaks going back to January of 2018, marked in red on the weekly chart. It's currently at $27, and falling fast. * Also note the gray 100-day moving average line is soon going to be tested as a technical ceiling. It has been a problem several times in the recent past, albeit not exactly. * It's small, but MYL stock has made a string of higher lows since May's low, plotted with a yellow line. It's the longest string of higher lows seen in well over year.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about him at his website jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 8 Worst Stocks to Buy Before the Trade Turmoil Cools Off * 7 'Strong Buy' Stocks to Beat Volatility * 7 Mega-Cap Tech Stocks on a Rebound Now The post 3 Big Stock Charts for Friday: Mylan, Newell and Home Depot appeared first on InvestorPlace.Fri, 30 Aug 2019 12:22:03 +0000 —Read more…U.S. FDA approves Mylan generic of Lilly lung cancer drug AlimtaThu, 29 Aug 2019 21:06:16 +0000 —Read more…Mylan Stock Leaps As It Prepares To Knock Off $2 Billion Lilly DrugMylan stock popped Thursday after the Food and Drug Administration tentatively approved its generic version of Eli Lilly's chemotherapy, Alimta. Lilly stock also rose in afternoon action.Thu, 29 Aug 2019 20:22:56 +0000 —Read more…Forget Pfizer, Add These Big Drugmakers to Your PortfolioBuy these three large drug companies instead of Pfizer (PFE) as the stock is down this year.Thu, 29 Aug 2019 13:06:01 +0000 —Read more…Mylan (MYL) Down 12.9% Since Last Earnings Report: Can It Rebound?Mylan (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.Wed, 28 Aug 2019 13:30:01 +0000 —Read more…4 Biotech Stocks to Buy That Are on the MoveU.S. equities bounded higher on Monday as President Donald Trump hinted that talks with Chinese officials over trade were continuing -- something that Beijing denied. On the surface, it looks like another Trump "Sunday Night Special" started the week off on a positive note after the futures were down hard in overnight trading.In other words, it looks like Trump is playing fast and loose with the facts to keep stock prices higher. Which for millions of investors watching their 401(k) balances, is just fine. * 10 Companies Using AI to Grow With trade temporarily removed as an issue to be concerned about, at least for today, investors are instead focusing on some corporate M&A activity in the biotechnology space. Biotech stocks overall, as represented by the iShares Biotechnology ETF (IBB), are holding up fairly well amid recent market volatility. A rebound to test the early July highs seems in order.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAnd these four stocks look ready to lead the way: Amgen (AMGN)Amgen (NASDAQ:AMGN) shares are testing their record highs near $205 after Bristol-Myers Squibb (NYSE:BMY) sold Celgene's (NASDAQ:CELG) Otezla psoriasis drug to the company for $13.4 billion in cash. All three of these stocks to buy are trading higher in response. The deal was done in response to an order by the Federal Trade Commission to secure BMY's acquisition of CELG as it already had a competitive anti-inflammatory psoriasis drug in its pipeline.The company will next report results on Oct. 29 after the close. Analysts are looking for earnings of $3.08 per share. When the company last reported on July 30, earnings of $3.97 per share beat estimates by 39 cents on a 3.1% decline in revenues. The company pays a 2.9% dividend yield. Bristol-Myers Squibb (BMY)BMY shares are testing above their 200-day moving average for the first time since the middle of 2018, rising out of a five-month consolidation range. Shares are benefiting from the sale of Celgene's Otezla drug to Amgen, satisfying regulatory requirements for its purchase of Celgene. The deal hinges on Celgene's pipeline of cancer-fighting drugs in development. * 7 "Boring" Stocks With Exciting Prospects The company is also being noticed for its dividend payout, which totals a 3.5% yield. BMY will next report results on Oct. 24 before the bell. Analysts are looking for earnings of $1.06 per share on revenues of $5.85 billion. When the company last reported on July 25, earnings of $1.18 beat estimates by 12 cents on a 10% rise in revenues. Celgene (CELG)Celgene's shares look ready to break out of a five-month consolidation range with a push up and over the $100-a-share level. As a reminder, the company's $74 billion buyout by Bristol-Myers Squibb works out to $50 in cash and one share of BMY, which is worth about $98 right now. This stock now basically trades as a derivative of BMY shares, as odds of the acquisition being approved move towards 100%.The company will next report results on Oct. 24. Analysts are looking for earnings of $2.70 per share on revenues of $4.39 billion. When the company last reported on July 30, earnings of $2.86 beat by 24 cents on a 15.4% rise in revenues. Mylan (MYL)Mylan (NASDAQ:MYL) shares look ready to rise off of a solid base of support near $19 that has been in play since late May. Back in July, the company agreed to combine with Pfizer's (NYSE:PFE) off-patent business, giving MYL's shareholders 43% of the combined company. Coverage of the stock was initiated back in June by Barclays analysts with an overweight rating.The company will next report results on Nov. 5 before the bell. Analysts are looking for earnings of $1.14 per share on revenues of $3 billion. When the company last reported on July 29, earnings of $1.03 per share beat estimates by eight cents on a 1.5% rise in revenues. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Companies Using AI to Grow * The 10 Biggest Winners From Second-Quarter Earnings * 7 Marijuana Penny Stocks to Consider for Those Who Can Handle Risk The post 4 Biotech Stocks to Buy That Are on the Move appeared first on InvestorPlace.Tue, 27 Aug 2019 15:01:27 +0000 —Read more…Historic Bear Signal Spells Bad News for Mylan StockThe 80-day trendline could push the drug stock even lowerMon, 26 Aug 2019 17:17:10 +0000 —Read more…Novo Nordisk Suing Mylan Over Generic Victoza DrugNews of Novo Nordisk suing Mylan is spreading as the two companies prepare for a legal battle.Source: joreks / Shutterstock.com The reason behind the upcoming legal battle has to do with Victoza. This is Novo Nordisk's (NYSE:NVO) drug for treating diabetes. Mylan (NASDAQ:MYL) is looking to market its own generic version of the drug, which is where the rub comes from.Novo Nordisk is seeking to block any efforts by Mylan to market its generic version of Victoza. Having a generic version of the drug available would eat into the revenue the company would make from selling its name brand version.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNovo Nordisk is also seeking to protect its products that still have patent protection. The patents surrounding Victoza will start expiring in July 2021 and the last one will reach its expiration date in March 2033, reports BioSpace.Novo Nordisk suing Mylan specifically has to do with this new drug from the latter being an alleged illegal generic of its own. The company is filing this lawsuit in response to an abbreviated new drug application filed by Mylan with the U.S. Food & Drug Administration. * 10 Marijuana Stocks That Could See 100% Gains, If Not More The lawsuit from Novo Nordisk against Mylan was filed on Monday. This had the company filing its lawsuit with the U.S. District Court for the District of Delaware. Lawsuits can be lengthy procedures, so it will likely be some time before we see the outcome of this one.NVO stock was up 1% and MYL stock was down slightly as of Thursday afternoon. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks That Could See 100% Gains, If Not More * 11 Stocks Under $10 to Buy Now * 6 China Stocks to Buy on the Dip As of this writing, William White did not hold a position in any of the aforementioned securities.The post Novo Nordisk Suing Mylan Over Generic Victoza Drug appeared first on InvestorPlace.Thu, 22 Aug 2019 18:39:06 +0000 —Read more…Denmark's Novo Nordisk files lawsuit against Mylan over patentThu, 22 Aug 2019 07:09:05 +0000 —Read more…Teva Launches Generic Version of Mylan's EpiPen for KIdsTeva (TEVA) launches generic version of Mylan's (MYL) popular EpiPen Jr allergy treatment at a price of $300 for a pack of two.Wed, 21 Aug 2019 15:04:03 +0000 —Read more…Teva to launch generic version of EpiPen for young childrenTeva Pharmaceutical Industries Ltd said on Tuesday its generic version of Mylan's EpiPen for young children will be available in most retail pharmacies at a price of $300 for a 2-pack. Israel-based Teva, the world's largest generic drugmaker, is already selling the product for adults, after getting U.S. approval for its copy of EpiPen in August following several years of delay. Mylan also produces a generic version of its own life-saving EpiPen allergy treatment, which like Teva's product is priced at about $300.Tue, 20 Aug 2019 12:23:31 +0000 —Read more…[video]Teva's Generic EpiPen Jr Is Now Available for $300There has been an EpiPen shortage in the U.S., Europe and Canada, thanks to manufacturing delays at Pfizer.Tue, 20 Aug 2019 09:31:00 +0000 —Read more…

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.

This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.

The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.

The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.

Disclaimer: Past performance is no guarantee of future performance. This product is for educational purposes only. Practical application of the products herein are at your own risk and MarketTamer.com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Any trades shown are hypothetical example and do not represent actual trades. Actual results may differ. Nothing here in constitutes a recommendation respecting the particular security illustrated.